Loading clinical trials...
Loading clinical trials...
Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)
Conditions
Interventions
Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg
Locations
1
Norway
Cardiovascular and Renal Research Center/ Department of Cardiology, Ullevaal University Hospital
Oslo, Norway
Start Date
December 1, 2004
Completion Date
July 1, 2005
Last Updated
July 6, 2011
NCT02417740
NCT07073820
NCT07480265
NCT06876233
NCT06062394
NCT06899815
Lead Sponsor
Ullevaal University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions